Published in Lancet on January 11, 2003
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer (2006) 4.46
Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res (2008) 2.30
Interstitial lung disease associated with drug therapy. Br J Cancer (2004) 1.64
Epithelial inflammation resulting from an inherited loss-of-function mutation in EGFR. J Invest Dermatol (2014) 1.58
A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. J Mol Diagn (2006) 1.50
Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer (2004) 1.05
Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LC03-02. BMC Res Notes (2009) 1.02
Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer (2007) 1.00
Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib. Clin Exp Nephrol (2008) 0.99
Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer (2004) 0.98
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer (2004) 0.96
New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know. Cancer Imaging (2014) 0.95
Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis. PLoS One (2011) 0.94
Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients. PLoS One (2011) 0.94
Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy. PLoS Med (2005) 0.94
Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. Br J Cancer (2003) 0.93
Sodium pentosan polysulfate resulted in cartilage improvement in knee osteoarthritis--an open clinical trial. BMC Clin Pharmacol (2010) 0.92
Current status of DILD in molecular targeted therapies. Int J Clin Oncol (2012) 0.92
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines. Mol Cancer (2011) 0.91
Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol (2015) 0.90
Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. J Med Case Rep (2007) 0.90
Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet (2003) 0.89
Tyrosine-kinase inhibition results in EGFR clustering at focal adhesions and consequent exocytosis in uPAR down-regulated cells of head and neck cancers. Mol Cancer (2008) 0.88
Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol (2012) 0.88
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer (2004) 0.88
Panitumumab in Japanese patients with unresectable colorectal cancer: a post-marketing surveillance study of 3085 patients. Jpn J Clin Oncol (2014) 0.87
Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction. PLoS One (2011) 0.87
Metabolism considerations for kinase inhibitors in cancer treatment. Expert Opin Drug Metab Toxicol (2010) 0.86
The role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of advanced stage non-small cell lung cancer. J Thorac Dis (2010) 0.86
Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis. Biomed Res Int (2013) 0.85
Successful treatment of gefitinib-induced acute interstitial pneumonitis with corticosteroid and non-invasive BIPAP-ventilation. J Thorac Dis (2012) 0.84
Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia. Oncotarget (2013) 0.83
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients. Cancer Res Treat (2015) 0.83
Long-term survival of a patient with lung cancer metastasis to the spine following surgical treatment combined with radiation and epithelial growth factor receptor inhibitor therapy: A case report. Exp Ther Med (2014) 0.82
Interstitial lung disease in patients with non-small-cell lung cancer: causes, mechanisms and management. Br J Cancer (2004) 0.81
Molecular mechanisms of cardiotoxicity induced by ErbB receptor inhibitor cancer therapeutics. Int J Mol Sci (2012) 0.81
Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings. Int J Clin Oncol (2012) 0.80
Incidence and clinical features of drug-induced lung injury in patients with advanced colorectal cancer receiving cetuximab: results of a prospective multicenter registry. Jpn J Clin Oncol (2014) 0.80
Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharm Pract (Granada) (2006) 0.80
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer. Br J Cancer (2006) 0.80
Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study. Int J Clin Oncol (2015) 0.80
Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients. Br J Cancer (2012) 0.80
EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. Drug Dev Res (2008) 0.80
Acute renal failure associated with gefitinib therapy. Lung (2006) 0.80
Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Respir Res (2011) 0.79
Molecular mechanisms of lung-specific toxicity induced by epidermal growth factor receptor tyrosine kinase inhibitors. Oncol Lett (2012) 0.79
Inhibition of fibrosis and inflammation by triple therapy with pirfenidone, edaravone and erythropoietin in rabbits with drug-induced lung injury: comparison of CT imaging and pathological findings. Exp Ther Med (2013) 0.79
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway. Oncotarget (2015) 0.79
Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature. BMC Cancer (2010) 0.78
Fatal interstitial lung disease associated with icotinib. J Thorac Dis (2014) 0.78
Cancer Phenotype Diagnosis and Drug Efficacy within Japanese Health Care. Int J Proteomics (2012) 0.78
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer (2004) 0.78
Gefitinib in combination with prednisolone to avoid interstitial lung disease during non-small cell lung cancer treatment: A case report. Oncol Lett (2013) 0.77
The role of epidermal growth factor receptor mutations and epidermal growth factor receptor-tyrosine kinase inhibitors in the treatment of lung cancer. Cancers (Basel) (2011) 0.76
Re-administration of gefitinib following diffuse interstitial lung disease in a patient with advanced lung adenocarcinoma: A case report and review of the literature. Oncol Lett (2015) 0.76
Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression. BMC Cancer (2013) 0.75
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells. PLoS One (2015) 0.75
A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer. Oncotarget (2016) 0.75
Clinical efficacy and toxiciy of gefitinib in patients with lung cancer. Lancet (2003) 0.75
Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic Non-Small Cell Lung Cancer: Case Report and Review of Literature. Rare Tumors (2016) 0.75
Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors. ScientificWorldJournal (2015) 0.75
Computational explanation for bioactivation mechanism of targeted anticancer agents mediated by cytochrome P450s: A case of Erlotinib. PLoS One (2017) 0.75
Crizotinib-induced toxicity in an experimental rat model. Wien Klin Wochenschr (2016) 0.75
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med (2010) 27.12
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Avian flu: influenza virus receptors in the human airway. Nature (2006) 11.28
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol (2006) 6.55
Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2005) 5.83
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol (2013) 4.30
First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol (2009) 4.05
Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell (2012) 3.90
Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2004) 2.35
Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med (2008) 2.29
Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. J Clin Invest (2005) 2.20
A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol (2008) 2.01
Methylation of the KEAP1 gene promoter region in human colorectal cancer. BMC Cancer (2012) 2.01
New terminology for intrauterine endometrial samples: a group study by the Japanese Society of Clinical Cytology. Acta Cytol (2012) 1.99
Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med (2006) 1.98
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol (2008) 1.88
Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer (2010) 1.79
Consensus statement for the diagnosis and treatment of drug-induced lung injuries. Respir Investig (2013) 1.70
Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7. EMBO J (2003) 1.68
Expression of urocortin and corticotropin-releasing factor receptor subtypes in the human heart. J Clin Endocrinol Metab (2002) 1.66
The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast (2007) 1.64
Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor. Cancer Res (2004) 1.63
High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway. Clin Cancer Res (2012) 1.56
Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. Psychiatry Clin Neurosci (2009) 1.54
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res (2009) 1.52
Genetics of synchronous uterine and ovarian endometrioid carcinoma: combined analyses of loss of heterozygosity, PTEN mutation, and microsatellite instability. Hum Pathol (2002) 1.51
Progesterone receptor in non-small cell lung cancer--a potent prognostic factor and possible target for endocrine therapy. Cancer Res (2005) 1.51
Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res (2002) 1.47
Persistence and compliance to antidepressant treatment in patients with depression: a chart review. BMC Psychiatry (2009) 1.44
The involvement of glucocorticoids in psychological stress-induced exacerbations of experimental allergic asthma. Int Arch Allergy Immunol (2014) 1.43
Contribution of high-mobility group box-1 to the development of ventilator-induced lung injury. Am J Respir Crit Care Med (2006) 1.42
Immunohistochemical assessment for estrogen receptor and progesterone receptor status in breast cancer: analysis for a cut-off point as the predictor for endocrine therapy. Breast Cancer (2004) 1.41
Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther (2010) 1.39
Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction. J Immunol (2002) 1.39
Development of Atrioventricular Block and Diagnostic Value of Stored Electrograms in Patients With Sick Sinus Syndrome and Implanted Pacemaker. Circ J (2015) 1.39
Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab (2003) 1.38
In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer (2005) 1.37
Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells (2007) 1.35
Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med (2010) 1.34
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol (2012) 1.33
Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors. J Antimicrob Chemother (2002) 1.31
Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol Med (2011) 1.31
Increased susceptibility to LPS-induced endotoxin shock in secretory leukoprotease inhibitor (SLPI)-deficient mice. J Exp Med (2003) 1.30
Anti-high-mobility group box chromosomal protein 1 antibodies improve survival of rats with sepsis. World J Surg (2006) 1.30
Expression of the steroid and xenobiotic receptor and its possible target gene, organic anion transporting polypeptide-A, in human breast carcinoma. Cancer Res (2006) 1.26
Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Res (2003) 1.25
Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol (2009) 1.24
Nuclear cyclin B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci (2007) 1.24
Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth. Cancer Res (2002) 1.22
Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res (2013) 1.21
OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest (2007) 1.21
Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J (2005) 1.19
Autoimmune pancreatitis with hepatic inflammatory pseudotumor. Pancreas (2005) 1.18
Overexpression of the Runx3 transcription factor increases the proportion of mature thymocytes of the CD8 single-positive lineage. J Immunol (2005) 1.17
Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer (2005) 1.17
Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res (2004) 1.16
Instabilotyping reveals unique mutational spectra in microsatellite-unstable gastric cancers. Cancer Res (2002) 1.16
Targeting apoptotic tumor cells to Fc gamma R provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol (2003) 1.16
Pulmonary mucinous cystadenocarcinoma: report of a case and review of the literature. Ann Thorac Surg (2003) 1.15
Hepatoid adenocarcinoma of the gallbladder: Case report and review of the literature. Pathol Int (2004) 1.14
Mannose-binding lectin gene polymorphism is a modulating factor in repeated respiratory infections. Chest (2004) 1.12
Systemic distribution of steroid sulfatase and estrogen sulfotransferase in human adult and fetal tissues. J Clin Endocrinol Metab (2002) 1.12
A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer. Clin Cancer Res (2012) 1.12
Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung. Carcinogenesis (2010) 1.12
Isolation and characterization of vasohibin-2 as a homologue of VEGF-inducible endothelium-derived angiogenesis inhibitor vasohibin. Arterioscler Thromb Vasc Biol (2006) 1.11
Therapeutic effect of lecithinized superoxide dismutase on bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2009) 1.09
Synchronous and metachronous extrapancreatic malignant neoplasms in patients with intraductal papillary-mucinous neoplasm of the pancreas. Pancreatology (2008) 1.08
Dendritic cells pulsed with live and dead Legionella pneumophila elicit distinct immune responses. J Immunol (2004) 1.08